Previous Close | 15.30 |
Open | 15.30 |
Bid | 21.85 |
Ask | 24.85 |
Strike | 190.00 |
Expire Date | 2024-06-21 |
Day's Range | 15.30 - 15.30 |
Contract Range | N/A |
Volume | |
Open Interest | 2 |
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.